CefixView: understanding trends in respiratory infections
DOI:
https://doi.org/10.18203/2319-2003.ijbcp20242429Keywords:
Cefixime, Cephalosporins, Streptococcus pneumonia, RTIsAbstract
Background: Respiratory tract infections (RTIs) are one of the most common infections in humans of all age groups and an important cause of mortality and morbidity worldwide. It can be classified as either acute or chronic. The bacterial species most commonly implicated in RTIs are Streptococcus pneumoniae, β-hemolytic Streptococci, Hemophilus influenzae, and Moraxella catarrhalis. Cefixime, a third-generation cephalosporin, is a bactericidal β-lactam antibiotic used to treat various bacterial infections. It is broad-spectrum and effective against gram-positive as well as gram-negative bacteria.
The primary objective is to understand the preferences, considerations, and clinical perspectives that influence the choice of cefixime among healthcare professionals, particularly in the management of RTIs.
Methods: It was a descriptive questionnaire-based cross-sectional study. The study was conducted among the physicians who attended the APICON-2024 and gave consent to participate in the study. A total 247 physicians registered their responses.
Results: Cefixime is preferred in indications like UTI, pharyngitis, Otitis media, typhoid fever, LRTIs, shigellosis, and dental infections. All the doctors (100%) use cefixime for the treatment of RTIs with varied frequency. The primary factor which influences the choice of cefixime for the management of RTIs is the broad-spectrum activity (46.75%) followed by a better safety profile (27.87%) and cost-effectiveness (15.08%). Overall, 92.73% of doctors view cefixime as a safe and reliable choice for the management of RTIs.
Conclusions: Cefixime has excellent tolerability and efficacy and is one of the most widely used drug in the treatment of respiratory infections.
Metrics
References
Respiratory tract infections-antibiotic prescribing (no date) National Center for Biotechnology Information. Available at: https://www.ncbi.nlm.nih.gov/books/NBK53632/#:~:text=Upper%20respiratory%20tract%20infections%20(URTIs,%2C%20bronchiolitis%2C%20pneumonia%20and%20tracheitis. Accessed on 25 June 2024.
Vikaspedia domains (no date) Vikaspedia. Available at: https://vikaspedia.in/health/diseases/lungs-related/acute-respiratory-infection-ari#:~:text=Acute%20respiratory%20infection%20prevents%20the,The%20disease%20is%20quite%20widespread. Accessed on 25 June 2024.
Murarkar S, Gothankar J, Doke P, Dhumale G, Pore PD, Lalwani S, et al. Prevalence of the Acute Respiratory Infections and Associated Factors in the Rural Areas and Urban Slum Areas of Western Maharashtra, India: A Community-Based Cross-Sectional Study. Front Public Health. 2021;9:723807.
Waghmode R, Jadhav S, Nema V. The Burden of Respiratory Viruses and Their Prevalence in Different Geographical Regions of India: 1970-2020. Front Microbiol. 2021;12:723850.
Thapa S, Gokhale S, Sharma AL, Sapkota LB, Ansari S, Gautam R, Shrestha S, Neopane P. Burden of bacterial upper respiratory tract pathogens in school children of Nepal. BMJ Open Respir Res. 2017;4(1):e000203.
Kumar SG, Majumdar A, Kumar V, Naik BN, Selvaraj K, Balajee K. Prevalence of acute respiratory infection among under-five children in urban and rural areas of puducherry, India. J Nat Sci Biol Med. 2015;6(1):3-6.
Cefixime - an overview ScienceDirect Topics. Available at: https://www.sciencedirect.com/topics/medicine-and-dentistry/cefixime. Accessed on 31 May 2024.
LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012. Cephalosporins. 2021.
Hamilton-Miller JM. Overview of cefixime use in community-acquired infections. Clin Microbiol Infect. 2000;6(3):79-81.
Ludwig E. Cefixime in the treatment of respiratory and urinary tract infections. Chemotherapy. 1998;44(1):31-4.
Ige OM, Okesola ao. comparative efficacy and safety of cefixime and ciprofloxacin in the management of adults with community-acquired pneumonia in Ibadan, Nigeria. Ann IB Postgrad Med. 2015;13(2):72-8.
Brogden RN, Campoli-Richards DM. Cefixime. A review of its antibacterial activity. Pharmacokinetic properties and therapeutic potential. Drugs. 1989;38(4):524-50.
Tan BJ. Cefixime use in children: When and why. Can J Infect Dis. 1995;6(4):204-5.
Block SL, Hedrick JA, Tyler RD. Comparative study of the effectiveness of cefixime and penicillin V for the treatment of Streptococcal pharyngitis in children and adolescents. Pediatr Infect Dis J. 1992;11:919-25.
Dreshaj SH, Doda-Ejupi T, Tolaj IQ, Mustafa A, Kabashi S, Shala N, et al. Clinical role of Cefixime in community-acquired infections. Prilozi. 2011;32(2):143-55.
De Lalla F. Cefixime in the treatment of upper respiratory tract infections and otitis media. Chemotherapy. 1998;44(1):19-23.
Matsumoto Y, Ikemoto A, Tawara S. ‘Antibacterial activity of cefixime against Salmonella typhi and applicability of Etest’. J Infect Chemother. 1999;5(3):176-9.
Begum B, Haque MA, Ahmed MS, Islam MN, Ahsan MM, Khan AH, et al. Comparison between azithromycin and cefixime in the treatment of typhoid fever in children. Mymensingh Med J. 2014;23(3):441-8.
Chaudhary MK. Efficacy of Cefixime in the Treatment of Typhoid Fever’. Int J Pharmaceut Biolog Arch. 2013;4(2):307-9.
Markham A, Brogden RN. Cefixime. A review of its therapeutic efficacy in lower respiratory tract infections. Drugs. 1995;49(6):1007-22.
Hausen Th, Weidlich G, Schmitt J: Safety and efficacy of cefixime in the treatment of respiratory tract infections in Germany. Infection. 1995;23(2):65-9.
Lorenz J, Steinfeld P, Drath L, Keienburg T, Troester K. Cefixime Short-Course versus Standard-Course Study Group. Efficacy and Tolerability of 5- vs 10-Day Cefixime Therapy in Acute Exacerbations of Chronic Bronchitis. Clin Drug Investig. 1998;15(1):13-20.
Downloads
Published
How to Cite
Issue
Section
